SREBP-1 and fatty liver. Clinical relevance for diabetes, obesity, dyslipidemia and atherosclerosis [SREBP-1 und Fettleber: Klinische Bedeutung für Diabetes, Adipositas, Dyslipidämie und Atherosklerose]

被引：2
作者：
Müller-Wieland D. [1 ]
Knebel B. [2 ]
Haas J. [1 ]
Kotzka J. [2 ]
机构：
[1] Erz-Gefäß-und Diabeteszentrum, Abteilung für Allgemeine Innere Medizin, Semmelweis-Universität, Lohmühlenstr. 5
[2] Institut für Klinische Biochemie und Pathobiochemie, Deutsches Diabetes-Zentrum, Heinrich-Heine-Universität, Düsseldorf
来源：
Herz | 2012年 / 37卷 / 3期
关键词：
Fatty liverNon-alcoholic fatty liver disease; Insulin resistance; Metabolic syndrome; Obesity;
D O I：
10.1007/s00059-012-3608-y
中图分类号：
学科分类号：
摘要：
AbstractInsulin resistance and visceral fat distribution usually play a major role in the development of clinical aspects of the metabolic syndrome, such as dyslipidemia, diabetes and atherosclerosis. In this review, the focus will be on some novel relationships with a fatty liver, for which susceptibility appears to be mediated by the activity of transcription factors, such as sterol regulatory element-binding protein 1 (SREBP-1). In addition to this molecular aspect therapeutic life-style modifications, such as weight reduction which are associated with increased insulin sensitivity and a decrease of fat in the liver will be discussed © 2012 Urban & Vogel.
引用
收藏
页码：273 / 280
页数：7
相关论文
共 41 条
  • [21] Knebel, B., Haas, J., Hartwig, S., Liver specific expression of transcriptional active SREBP-1c is associated with fatty liver and increase fat mass (2012) PLoS One, 7 (2), pp. e31812
  • [22] Kotzka, J., Knebel, B., Haas, J., Preventing phosphorylation of sterol regulatory element-binding protein 1a by MAP-kinases protects mice from fatty liver and visceral obesity (2012) PLoS One, 7 (2), pp. e32609
  • [23] Kotzka, J., Knebel, B., Janssen, O.E., Identification of a gene variant in the master regulator of lipid metabolism SREBP-1 in a family with a novel form of severe combined hypolidaemia (2011) Atherosclerosis, 218, pp. 134-143
  • [24] McGarry, J.D., What if Minkowski had been ageusic? An alternative angle on diabetes (1992) Science, 258, pp. 766-770
  • [25] Biddinger, S.B., Hernandez-Ono, A., Rask-Madsen, C., Haas, J.T., Aleman, J.O., Suzuki, R., Scapa, E.F., Kahn, C.R., Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis (2008) Cell Metabolism, 7 (2), pp. 125-134. , DOI 10.1016/j.cmet.2007.11.013, PII S1550413107003683
  • [26] Unger, R.H., Lipotoxic diseases (2002) Annu Rev Med, 53, pp. 19-36
  • [27] Brown, M.S., Goldstein, J.L., The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor (1997) Cell, 89 (3), pp. 331-340. , DOI 10.1016/S0092-8674(00)80213-5
  • [28] Brown, M.S., Goldstein, J.L., A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood (1999) Proceedings of the National Academy of Sciences of the United States of America, 96 (20), pp. 11041-11048. , DOI 10.1073/pnas.96.20.11041
  • [29] Kotzka, J., Muller-Wieland, D., Sterol regulatory element-binding protein (SREBP)-1: Gene regulatory target for insulin resistance? (2004) Expert Opinion on Therapeutic Targets, 8 (2), pp. 141-149. , DOI 10.1517/14728222.8.2.141
  • [30] Tang, J.J., Li, J.G., Qi, W., Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques (2011) Cell Metab, 13, pp. 44-56
12345